NASDAQ:PRTG Portage Biotech (PRTG) Stock Forecast, Price & News $3.84 +0.08 (+2.13%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$3.74▼$3.9750-Day Range$2.73▼$3.7752-Week Range$2.34▼$11.99Volume23,489 shsAverage Volume30,609 shsMarket Capitalization$64.96 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Portage Biotech MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside395.4% Upside$19.00 Price TargetShort InterestHealthy0.41% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.57Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.94) to ($1.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.27 out of 5 starsMedical Sector255th out of 986 stocksCrude Petroleum & Natural Gas Industry56th out of 78 stocks 3.5 Analyst's Opinion Consensus RatingPortage Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.00, Portage Biotech has a forecasted upside of 395.4% from its current price of $3.84.Amount of Analyst CoveragePortage Biotech has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.41% of the float of Portage Biotech has been sold short.Short Interest Ratio / Days to CoverPortage Biotech has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Portage Biotech has recently decreased by 10.44%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPortage Biotech does not currently pay a dividend.Dividend GrowthPortage Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRTG. Previous Next 2.0 News and Social Media Coverage News SentimentPortage Biotech has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Portage Biotech this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Portage Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders42.07% of the stock of Portage Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.67% of the stock of Portage Biotech is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Portage Biotech are expected to decrease in the coming year, from ($0.94) to ($1.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Portage Biotech is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Portage Biotech is -3.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPortage Biotech has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Portage Biotech (NASDAQ:PRTG) StockPortage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; TT-10, an adenosine receptor type 2A (A2A) inhibitor to treat A2A expressing solid tumors; TT-4, an adenosine receptor type 2B (A2B) inhibitor to treat solid tumors; TT-53, an A2A/A2B inhibitor to treat solid tumors; TT-3, an A2B inhibitor to treat colorectal and gastrointestinal cancers; and NT230-6 that is in Phase I/II clinical trials for the treatment of tumors. It also provides Nanolipogel (NLG) co-formulation platform for delivery of DNA aptamers and certain aptamer-small molecule-based combination products; and STING agonist platform, a proprietary immune priming and boosting technology, offers various ways to target immune stimulation towards the cancer, as well as to co-deliver various signals in a single product. The company is based in Tortola, British Virgin Islands.Read More Receive PRTG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Portage Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address PRTG Stock News HeadlinesJune 5, 2023 | benzinga.comWhy Portage Biotech Stock Is Up TodayJune 5, 2023 | finance.yahoo.comPortage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual MeetingJune 8, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>June 1, 2023 | finance.yahoo.comPortage Biotech to Participate in Panel Discussion During the 2023 BIO International ConferenceMay 11, 2023 | americanbankingnews.comPortage Biotech Inc. (NASDAQ:PRTG) Short Interest Down 34.8% in AprilApril 29, 2023 | usnews.comPortage Central High SchoolApril 26, 2023 | finance.yahoo.comPortage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingApril 19, 2023 | usnews.comPortage High SchoolJune 8, 2023 | Altimetry (Ad)Pentagon Consultant—Here's how Biden Wins Landslide Re-election—but also hand Joe Biden a landslide re-election win. What would America look like if we slide further towards Socialism? Full story and 4 steps you can take,April 12, 2023 | nytimes.comTrack Covid-19 in Portage County, WisconsinMarch 12, 2023 | benzinga.comPortage Biotech Stock (NASDAQ:PRTG), DividendsMarch 7, 2023 | finance.yahoo.comPortage Biotech to Present at Oppenheimer’s 33rd Annual Healthcare ConferenceMarch 1, 2023 | finance.yahoo.comPortage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022February 27, 2023 | finance.yahoo.comPortage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in CancerFebruary 23, 2023 | msn.comPortage Biotech reports FY resultsFebruary 15, 2023 | finance.yahoo.comPortage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership SummitJanuary 21, 2023 | seekingalpha.comPRTG Portage Biotech Inc.December 2, 2022 | nasdaq.comHow Much Upside is Left in Portage Biotech Inc. (PRTG)? Wall Street Analysts Think 160%November 30, 2022 | finance.yahoo.comPortage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022November 10, 2022 | technews.tmcnet.comPortage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer's (SITC) 37th Annual MeetingNovember 10, 2022 | finance.yahoo.comPortage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual MeetingNovember 8, 2022 | finance.yahoo.comPortage Biotech Announces Clinical Trial Collaboration Agreement with MerckSeptember 23, 2022 | benzinga.com7PRTG : HC Wainwright & Co. Maintains Buy...September 19, 2022 | nasdaq.comHow Much Upside is Left in Portage Biotech Inc. (PRTG)? Wall Street Analysts Think 268%September 19, 2022 | nasdaq.comBears are Losing Control Over Portage Biotech Inc. (PRTG), Here's Why It's a 'Buy' NowSeptember 8, 2022 | finance.yahoo.comPortage Biotech to Present at Upcoming Investor ConferencesAugust 31, 2022 | seekingalpha.comPortage Biotech GAAP EPS of -$0.13See More Headlines PRTG Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRTG Company Calendar Last Earnings11/22/2021Today6/08/2023Next Earnings (Estimated)8/07/2023Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Crude petroleum & natural gas Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRTG CUSIPN/A CIK1095435 Webwww.portagebiotech.com Phone416-929-1806FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$19.00 High Stock Price Forecast$21.00 Low Stock Price Forecast$18.00 Forecasted Upside/Downside+406.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,870,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-10.34% Return on Assets-8.58% Debt Debt-to-Equity RatioN/A Current Ratio6.41 Quick Ratio6.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$12.40 per share Price / Book0.30Miscellaneous Outstanding Shares16,940,000Free Float9,816,000Market Cap$63.59 million OptionableNot Optionable Beta1.30 Key ExecutivesDr. Ian B. Walters M.B.A. (Age 54)M.D., CEO & Chairman of Board Comp: $848.15kMr. Allan J. Lee Shaw CPA (Age 58)Chief Financial Officer Comp: $430.95kMr. Steven InnaimoVP of Project Management & OperationsDr. Robert A. Kramer Ph.D.Chief Scientific OfficerMr. Brian Wiley (Age 54)Chief Bus. Officer Comp: $252.17kMr. Joseph CiavarellaChief Accounting OfficerMore ExecutivesKey CompetitorsTradeUP AcquisitionNASDAQ:UPTDSonendoNYSE:SONXMyMD PharmaceuticalsNASDAQ:MYMDHookipa PharmaNASDAQ:HOOKAlzamend NeuroNASDAQ:ALZNView All CompetitorsInstitutional OwnershipMAI Capital ManagementBought 21,164 shares on 5/10/2023Ownership: 0.464%Simplex Trading LLCBought 400 shares on 4/27/2023Ownership: 0.000%View All Institutional Transactions PRTG Stock - Frequently Asked Questions Should I buy or sell Portage Biotech stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Portage Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PRTG shares. View PRTG analyst ratings or view top-rated stocks. What is Portage Biotech's stock price forecast for 2023? 3 Wall Street research analysts have issued 1 year price targets for Portage Biotech's shares. Their PRTG share price forecasts range from $18.00 to $21.00. On average, they anticipate the company's share price to reach $19.00 in the next year. This suggests a possible upside of 406.1% from the stock's current price. View analysts price targets for PRTG or view top-rated stocks among Wall Street analysts. How have PRTG shares performed in 2023? Portage Biotech's stock was trading at $5.2891 at the start of the year. Since then, PRTG shares have decreased by 29.0% and is now trading at $3.7539. View the best growth stocks for 2023 here. When is Portage Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023. View our PRTG earnings forecast. How were Portage Biotech's earnings last quarter? Portage Biotech Inc. (NASDAQ:PRTG) released its quarterly earnings results on Monday, November, 22nd. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.03. What is Portage Biotech's stock symbol? Portage Biotech trades on the NASDAQ under the ticker symbol "PRTG." Who are Portage Biotech's major shareholders? Portage Biotech's stock is owned by a number of institutional and retail investors. Top institutional shareholders include MAI Capital Management (0.46%) and Simplex Trading LLC (0.00%). How do I buy shares of Portage Biotech? Shares of PRTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Portage Biotech's stock price today? One share of PRTG stock can currently be purchased for approximately $3.75. How much money does Portage Biotech make? Portage Biotech (NASDAQ:PRTG) has a market capitalization of $63.59 million. The company earns $-16,870,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. How can I contact Portage Biotech? Portage Biotech's mailing address is Craigmuir Chambers Road Town, Tortola D8, VG1110. The official website for the company is www.portagebiotech.com. The company can be reached via phone at 416-929-1806. This page (NASDAQ:PRTG) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Portage Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.